Back to Search
Start Over
A manganese-doped layered double hydroxide loaded with lactate oxidase and DNA repair inhibitors for synergistically enhanced tumor immunotherapy.
- Source :
-
Acta biomaterialia [Acta Biomater] 2024 Oct 01; Vol. 187, pp. 340-351. Date of Electronic Publication: 2024 Aug 30. - Publication Year :
- 2024
-
Abstract
- Tumor immunotherapy has gained more and more attention in tumor treatment. However, the accumulation of lactic acid in tumor tissue inhibits the response of immune cells to form an immunosuppressive microenvironment (ISME). To reverse the ISME, an acid-responsive nanoplatform (termed as MLLN@HA) is reported for synergistically enhanced tumor immunotherapy. MLLN@HA is constructed by the co-loading of lactate oxidase (LOX) and DNA repair inhibitor (NU7441) in a manganese-doped layered double hydroxide (Mn-LDH), and then modified with hyaluronic acid (HA) for tumor-targeted delivery. After endocytosis by tumor cells, MLLN@HA decomposes and releases LOX, NU7441 and Mn <superscript>2+</superscript> ions in the acidic tumor microenvironment. The released LOX catalyzes the conversion of lactic acid into hydrogen peroxide (H <subscript>2</subscript> O <subscript>2</subscript> ), which not only alleviates the ISME, but also provides reactants for the Mn <superscript>2+</superscript> -mediated Fenton-like reaction to enhance chemodynamic therapy (CDT). Released NU7441 prevents CDT-induced DNA damage from being repaired, thereby increasing double-stranded DNA (dsDNA) fragments within tumor cells. Importantly, the released Mn <superscript>2+</superscript> ions enhance the sensitivity of cyclic GMP-AMP synthase (cGAS) to dsDNA fragments, and activate the stimulator of interferon genes (STING) to induce an anti-tumor immune response. Such an orchestrated immune-boosting strategy ultimately achieves effective tumor growth inhibition and prevents tumor lung metastasis. STATEMENT OF SIGNIFICANCE: To improve the efficacy of tumor immunotherapy, an innovative acid-responsive MLLN@HA nanoplatform was developed for synergistically enhanced tumor immunotherapy. The MLLN@HA actively targets to tumor cells through the interaction of HA with CD44, and then degrades to release LOX, NU7441 and Mn <superscript>2+</superscript> ions in the acidic tumor microenvironment. The released LOX generates H <subscript>2</subscript> O <subscript>2</subscript> for the Mn <superscript>2+</superscript> -mediated Fenton reaction and reverses the ISME by consuming lactate. NU7441 prevents DNA damage repair, leading to an increased concentration of free DNA fragments, while Mn <superscript>2+</superscript> ions activate the cGAS-STING pathway, enhancing the systemic anti-tumor immune response. The orchestrated immune-boosting nanoplatform effectively inhibits tumor growth and lung metastasis, presenting a promising strategy for cancer treatment.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)
- Subjects :
- Animals
Mice
Cell Line, Tumor
Hydroxides chemistry
Hydroxides pharmacology
Humans
Tumor Microenvironment drug effects
Neoplasms pathology
Neoplasms therapy
Neoplasms drug therapy
Hyaluronic Acid chemistry
Manganese chemistry
Manganese pharmacology
Immunotherapy methods
DNA Repair drug effects
Mixed Function Oxygenases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1878-7568
- Volume :
- 187
- Database :
- MEDLINE
- Journal :
- Acta biomaterialia
- Publication Type :
- Academic Journal
- Accession number :
- 39218280
- Full Text :
- https://doi.org/10.1016/j.actbio.2024.08.045